Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas

Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas

<p>Drug Screening Data</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Gerhard Jungwirth (15047922) (author)
Бусад зохиолчид:	Tao Yu (15047925) (author), Fang Liu (15047928) (author), Junguo Cao (15047931) (author), Montadar Alaa Eddine (15047934) (author), Mahmoud Moustafa (15047937) (author), Amir Abdollahi (15026702) (author), Rolf Warta (15047940) (author), Andreas Unterberg (15047943) (author), Christel Herold-Mende (15047946) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development CNS Cancers Small Molecule Agents Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Figure 2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure 3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure 5 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure 6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure 7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S10 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S5 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S8 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Figure S9 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Table 1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
-н: Emily E. Seiden (22436851)
Хэвлэсэн: (2025)

Overview of 35 venom-derived peptide drugs, including their sequences, pharmacological activities, and regulatory status (FDA-approved or in clinical trials).
-н: Rimsha Bibi (20405012)
Хэвлэсэн: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
-н: Francesca Orzan (15055579)
Хэвлэсэн: (2025)

Supplemental Table 1 from Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
-н: Zachary J. Walker (19135313)
Хэвлэсэн: (2025)

Supplemental Table 2 from Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
-н: Zachary J. Walker (19135313)
Хэвлэсэн: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
-н: Sied Kebir (15048732)
Хэвлэсэн: (2025)

Figure 1 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 2 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 3 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 4 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 5 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 6 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Figure 7 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
-н: Elisa Izquierdo (15110795)
Хэвлэсэн: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
-н: William Kelly (15439117)
Хэвлэсэн: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
-н: William Kelly (15439117)
Хэвлэсэн: (2025)

Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
-н: Imran Khan (15056870)
Хэвлэсэн: (2025)

Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
-н: Imran Khan (15056870)
Хэвлэсэн: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
-н: David Olayinka Kamson (16617218)
Хэвлэсэн: (2025)